Newswire (Published: Thursday, October 8, 2020, Received: Thursday, October 8, 2020, 6:29:39 PM CDT)

Word Count: 528

2020 OCT 08 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators publish new report on Health and Medicine - Prostate Research. According to news reporting from San Francisco, California, by NewsRx journalists, research stated, “For biopsies with Gleason 3 + 3 = 6 or 3 + 4 = 7 prostate cancer, the Genomic Prostate Score (GPS; OncotypeDx) is designed to predict severe pathology at prostatectomy, and, in some cases, recommends reclassification of the National Comprehensive Cancer Network (NCCN) risk category. We hypothesized that certain histopathologic features that were not considered in the original design of the assay actually would be associated with the NCCN risk category change indicated by GPS testing.”

The news correspondents obtained a quote from the research from the University of California San Francisco (UCSF), “For patients with recommended NCCN risk category change, the biopsy cores used for GPS were re-reviewed for stromal reaction, chronic inflammation, and tumor nuclear polarization. Of 520 patients from May 2011 to December 2018, GPS testing suggested NCCN risk reclassification in 131 (25%); 127 of these slides were available. Of these, the NCCN risk category increased from intermediate to high in 8, low to intermediate in 15, very low to low in 1, and decreased from intermediate to low in 32, and low to very low in 71. Biopsies with NCCN risk increase were associated with moderate or severe stromal reaction (p < .001) and chronic inflammation (p < .001); biopsies with NCCN risk decrease were associated with absence of these features. In Gleason 3 + 3 = 6 cases (n = 93), presence of nuclear polarization was associated with NCCN risk decrease and its absence with increase (p < .001). Moderate or severe stromal reaction, chronic inflammation, and lack of nuclear polarization in Gleason score 3 + 3 = 6 tumors were each associated with an increase in NCCN risk category indicated by GPS and vice versa.”

According to the news reporters, the research concluded: “Our results suggest that GPS captures histologic features associated with aggressiveness that are not routinely assessed in standard histopathologic assessments, and that consideration of such histologic features may improve upon current tumor grading approaches.”

This research has been peer-reviewed.

For more information on this research see: Prostate Biopsy Histopathologic Features Correlate With a Commercial Gene Expression Assay’s Reclassification of Patient Nccn Risk Category. The Prostate, 2020;():. The Prostate can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.

Our news journalists report that additional information may be obtained by contacting Nancy Y. Greenland, University of California San Francisco (UCSF), Dept. of Anatomical Pathology, San Francisco, CA 94143, United States. Additional authors for this research include Emily Chan, Bradley A. Stohr, Jeffry P. Simko, Janet E. Cowan and Peter R. Carroll.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/pros.24072. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Places

North America
United States
Americas
California
San Francisco

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research